Epstein-Barr virus gene expression and latent membrane protein 1 gene polymorphism in pediatric liver transplant recipients

Journal of Medical Virology

Volumn 83, Issue 12, 2011, Pages 2182-2190

  Kasztelewicz, Beata ^a   Jankowska, Irena ^a   Pawłowska, Joanna ^a   Teisseyre, Joanna ^a   Dzierzanowska Fangrat, Katarzyna ^a  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

EBV DNA load; EBV latency type; Human Herpesvirus 4; Real time PCR

Indexed keywords

CYCLOSPORIN; EPSTEIN BARR VIRUS ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN 2; IMMEDIATE EARLY PROTEIN BZLF1; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; VIRUS DNA;

ADOLESCENT; ANIMAL CELL; ARTICLE; BILE DUCT ATRESIA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; GENE ACTIVITY; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INFECTIOUS MONONUCLEOSIS; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER HEMANGIOMA; LIVER TRANSPLANTATION; MALE; NONHUMAN; PEDIATRIC SURGERY; PRESCHOOL CHILD; PROSPECTIVE STUDY; PROTEIN VARIANT; QUANTITATIVE ANALYSIS; SCHOOL CHILD; VIRUS GENE; VIRUS LATENCY; VIRUS LOAD; WILD TYPE;

ADOLESCENT; BLOOD; CHILD; CHILD, PRESCHOOL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GENE EXPRESSION PROFILING; GENETIC VARIATION; HERPESVIRUS 4, HUMAN; HUMANS; INFANT; LIVER TRANSPLANTATION; MALE; TRANSPLANTATION; VIRAL LOAD; VIRAL MATRIX PROTEINS; VIREMIA;

HUMAN HERPESVIRUS 4;

EID: 80054857735     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22242     Document Type: Article

References (36)

1. Babcock GJ, Hochberg D, Thorley-Lawson DA. 2000. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13: 497-506.
2. Blake SMS, Eliopoulos AG, Dawson CW, Young LS. 2001. The transmembrane domains of the EBV-encoded latent membrane protein 1 (LMP1) variant CAO regulate enhanced signalling activity. Virology 282: 278-287.
3. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R. 1998. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9: 405-411.
4. Chang CM, Yu KJ, Mbulaiteye SM, Hildesheim A, Bhatia K. 2009. The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: A need for reappraisal. Virus Res 143: 209-221.
5. Chen ML, Tsai CN, Liang CL, Shu CH, Huang CR, Sulitzeanu D, Liu ST, Chang YS. 1992. Cloning and characterization of the latent membrane-protein (LMP) of a specific Epstein-Barr-virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. Oncogene 7: 2131-2140.
6. Dawson CW, Eliopoulos AG, Blake SM, Barker R, Young LS. 2000. Identification of functional differences between prototype Epstein-Barr virus-encoded LMP1 and a nasopharyngeal carcinoma-derived LMP1 in human epithelial cells. Virology 272: 204-217.
7. Gotoh K, Ito Y, Ohta R, Iwata S, Nishiyama Y, Nakamura T, Kaneko K, Kiuchi T, Ando H, Kimura H. 2010. Immunologic and virologic analyses in pediatric liver transplant recipients with chronic high Epstein-Barr virus loads. J Infect Dis 202: 461-469.
8. Henderson S, Rowe M, Gregory C, Croomcarter D, Wang F, Longnecker R, Kieff E, Rickinson A. 1991. Induction of Bcl-2 expression by Epstein-Barr-virus latent membrane protein-1 protects infected B-cells from programmed cell-death. Cell 65: 1107-1115.
9. Hu LF, Chen F, Zheng X, Ernberg I, Cao SL, Christensson B, Klein G, Winberg G. 1993. Clonability and tumorigenicity of human epithelial-cells expressing the EBV encoded membrane-protein LMP1. Oncogene 8: 1575-1583.
10. Iwata S, Wada K, Tobita S, Gotoh K, Ito Y, Demachi-Okamura A, Shimizu N, Nishiyama Y, Kimura H. 2010. Quantitative analysis of Epstein-Barr virus (EBV)-related gene expression in patients with chronic active EBV infection. J Gen Virol 91: 42-50.
11. Jabs WJ, Hennig H, Kittel M, Pethig K, Smets F, Bucsky P, Kirchner H, Wagner HJ. 2001. Normalized quantification by real-time PCR of Epstein-Barr virus load in patients at risk for posttransplant lymphoproliferative disorders. J Clin Microbiol 39: 564-569.
12. Jang JY, Kim KM, Lee YJ, Lee SG, Chi HS. 2008. Quantitative Epstein-Barr virus viral load monitoring in pediatric liver transplantation. Transplant Proc 40: 2546-2548.
13. Johnson RJ, Stack M, Hazlewood SA, Jones M, Blackmore CG, Hu LF, Rowe M. 1998. The 30-base-pair deletion in Chinese variants of the Epstein-Barr virus LMP1 gene is not the major effector of functional differences between variant LMP1 genes in human lymphocytes. J Virol 72: 4038-4048.
14. Knipe D, Howley P. 2001. Fields virology, 4th edition. Philadelphia: Lippinot Williams & Wilkins (LWW). 2590 p.
15. Kubota N, Wada K, Ito Y, Shimoyama Y, Nakamura S, Nishiyama Y, Kimura H. 2008. One-step multiplex real-time PCR assay to analyse the latency patterns of Epstein-Barr virus infection. J Virol Methods 147: 26-36.
16. Kullberg-Lindh C, Ascher H, Saalman R, Olausson M, Lindh M. 2006. Epstein-Barr viremia levels after pediatric liver transplantation as measured by real-time polymerase chain reaction. Pediatr Transplant 10: 83-89.
17. Kuppers R. 2003. B cells under influence: Transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 3: 801-812.
18. Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Barshes NR, Scott JD, Bristow LJ, O'Mahony CA, Goss JA. 2005. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 5: 2222-2228.
19. Mehl AM, Fischer N, Rowe M, Hartmann F, Daus H, Trumper L, Pfreundschuh M, Muller-Lantzsch N, Grasser FA. 1998. Isolation and analysis of two strongly transforming isoforms of the Epstein-Barr-virus (EBV)-encoded latent membrane protein-1 (LMP1) from a single Hodgkin's lymphoma. Int J Cancer 76: 194-200.
20. Niedobitek G, Agathanggelou A, Herbst H, Whitehead L, Wright DH, Young LS. 1997. Epstein-Barr virus (EBV) infection in infectious mononucleosis: Virus latency, replication and phenotype of EBV-infected cells. J Pathol 182: 151-159.
21. Peng M, Lundgren E. 1992. Transient expression of the Epstein-Barr-virus LMP1 gene in human primary B-cells induces cellular activation and DNA-synthesis. Oncogene 7: 1775-1782.
22. Qu LR, Green M, Webber S, Reyes J, Ellis D, Rowe D. 2000. Epstein-Barr virus gene expression in the peripheral blood of transplant recipients with persistent circulating virus loads. J Infect Dis 182: 1013-1021.
23. Rickinson AB, Moss DJ. 1997. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 15: 405-431.
24. Roughan JE, Thorley-Lawson DA. 2009. The intersection of Epstein-Barr virus with the germinal center. J Virol 83: 3968-3976.
25. Rowe M, Niedobitek G, Young LS. 1998. Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders. Springer Semin Immunopathol 20: 389-403.
26. Sandvej K, Gratama JW, Munch M, Zhou XG, Bolhuis RLH, Andresen BS, Gregersen N, Hamilton-Dutoit S. 1997. Sequence analysis of the Epstein-Barr virus (EBV) latent membrane protein-1 gene and promoter region: Identification of four variants among wild-type EBV isolates. Blood 90: 323-330.
27. Scheenstra R, Verschuuren EAM, de Haan A, Slooff MJH, The TH, Bijleveld CMA, Verkade HJ. 2004. The value of prospective monitoring of Epstein-Barr virus DNA in blood samples of pediatric liver transplant recipients. Transplant Infect Dis 6: 15-22.
28. Spada M, Guizzetti M, Petz W, Colledan M, Segalin A, Lucianetti A, Bertani A, Peloni G, Sonzogni A, Alberti D, Riva S, Melzi M, Gridelli B. 2001. Circulating EBV-DNA in the monitoring of EBV infection in pediatric liver transplant recipients. Transplant Proc 33: 1835-1837.
29. Tacyildiz N, Cavdar AO, Ertem U, Oksal A, Kutluay L, Uluoglu O, Lin JC. 1998. Unusually high frequency of a 69-bp deletion within the carboxy terminus of the LMP-1 oncogene of Epstein-Barr virus detected in Burkitt's lymphoma of Turkish children. Leukemia 12: 1796-1805.
30. Thorley-Lawson DA. 2001. Epstein-Barr virus: Exploiting the immune system. Nat Rev Immunol 1: 75-82.
31. Thorley-Lawson DA. 2005. EBV the prototypical human tumor virus-Just how bad is it? J Allergy Clin Immunol 116: 251-261.
32. Thorley-Lawson DA, Allday MJ. 2008. The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nat Rev Microbiol 6: 913-924.
33. Tierney RJ, Steven N, Young LS, Rickinson AB. 1994. Epstein-Barr virus latency in blood mononuclear-cells-Analysis of viral gene-transcription during primary infection and in the carrier state. J Virol 68: 7374-7385.
34. Uchida J, Yasui T, Takaoka-Shichijo Y, Muraoka M, Kulwichit W, Raab-Traub N, Kikutani H. 1999. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science 286: 300-303.
35. Young LS, Dawson CW, Eliopoulos AG. 2000. The expression and function of Epstein-Barr virus encoded latent genes. J Clin Pathol 53: 238-247.
36. Young LS, Rickinson AB. 2004. Epstein-Barr virus: 40 years on. Nat Rev Cancer 4: 757-768.